SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Suven Life Sciences surges on reporting two-fold rise in Q4 net profit

07 May 2012 Evaluate

Suven Life Sciences is currently trading at Rs. 16.20, up by 0.25 points or 1.57% from its previous closing of Rs. 15.95 on the BSE.

The scrip opened at Rs. 15.80 and has touched a high and low of Rs. 16.60 and Rs. 15.80 respectively. So far 33879 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 1 has touched a 52 week high of Rs. 23.65 on 02-Jun-2011 and a 52 week low of Rs. 11.50 on 02-Jan-2012.

Last one week high and low of the scrip stood at Rs. 17.15 and Rs. 15.05 respectively. The current market cap of the company is Rs. 186.19 crore.

The promoters holding in the company stood at 63.44% while Institutions and Non-Institutions held 0.08% and 36.48% respectively.

Suven Life Sciences has reported results for fourth quarter ended March 31, 2011.

On the standalone basis, the company has posted a rise of 137.14% in its net profit at Rs 8.30 crore for the quarter ended March 31, 2012 as compared to Rs 3.50 crore for the same quarter in the previous year. Total income has increased by 36.96% at Rs 62.51 crore for quarter under review as compared to Rs 45.64 crore for the quarter ended March 31, 2011.

Suven Life Sciences is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products, which are first in class or best in class therapies through the use of GPCR targets.

Suven Life Sciences Share Price

208.90 13.00 (6.64%)
20-Apr-2026 14:37 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1668.90
Dr. Reddys Lab 1235.10
Cipla 1232.95
Zydus Lifesciences 936.50
Lupin 2327.10
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×